Targeted Therapy in Chronic Lymphocytic Leukemia (CLL)

Erin M. Pettijohn, Shuo Ma*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


The standard of care for the treatment of chronic lymphocytic leukemia (CLL) has traditionally been chemoimmunotherapy. For patients who are unable to tolerate chemotherapy and those with high risk 17p deletions, there were previously few feasible or efficacious treatment options. Novel targeted agents for the treatment of CLL have the potential to offer long-term, durable remissions and offer promising treatment options for those in previously challenging population groups. Current targeted agents in CLL are directed against B cell receptor-associated tyrosine kinases such as BTK and SYK, the downstream PI3-kinase pathway, as well as the antiapoptotic protein BCL-2. The optimal sequencing of these agents has yet to be determined, although the side effect profile differs significantly and may dictate choice of therapy until further randomized data becomes available.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalCurrent Hematologic Malignancy Reports
Issue number1
StatePublished - Feb 1 2017


  • BCL2 inhibitor
  • BTK inhibitor
  • Chronic lymphocytic leukemia
  • PI3K inhibitor
  • Review
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeted Therapy in Chronic Lymphocytic Leukemia (CLL)'. Together they form a unique fingerprint.

Cite this